KR101048657B1 - 실크 아미노산 및 티로신을 유효성분으로 포함하는 뇌질환 예방 및 개선용 조성물 - Google Patents
실크 아미노산 및 티로신을 유효성분으로 포함하는 뇌질환 예방 및 개선용 조성물 Download PDFInfo
- Publication number
- KR101048657B1 KR101048657B1 KR1020100077583A KR20100077583A KR101048657B1 KR 101048657 B1 KR101048657 B1 KR 101048657B1 KR 1020100077583 A KR1020100077583 A KR 1020100077583A KR 20100077583 A KR20100077583 A KR 20100077583A KR 101048657 B1 KR101048657 B1 KR 101048657B1
- Authority
- KR
- South Korea
- Prior art keywords
- tyrosine
- composition
- silk amino
- amino acid
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title claims abstract description 59
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title claims abstract description 58
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 45
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 76
- 229960003638 dopamine Drugs 0.000 claims abstract description 38
- 210000002569 neuron Anatomy 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 8
- 230000006806 disease prevention Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 210000005064 dopaminergic neuron Anatomy 0.000 claims description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 239000012141 concentrate Substances 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 35
- 208000014644 Brain disease Diseases 0.000 description 31
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 26
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 19
- 239000013641 positive control Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 241000255789 Bombyx mori Species 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000001120 cytoprotective effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 210000004744 fore-foot Anatomy 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010013296 Sericins Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000193935 Araneus diadematus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 241000238902 Nephila clavipes Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- -1 oral preparations Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100077583A KR101048657B1 (ko) | 2010-08-11 | 2010-08-11 | 실크 아미노산 및 티로신을 유효성분으로 포함하는 뇌질환 예방 및 개선용 조성물 |
| CN2011800493075A CN103209697A (zh) | 2010-08-11 | 2011-08-10 | 包含丝氨基酸和酪氨酸的用于预防及改善脑疾病的组合物 |
| PCT/KR2011/005853 WO2012020991A2 (ko) | 2010-08-11 | 2011-08-10 | 실크 아미노산 및 티로신을 유효성분으로 포함하는 뇌질환 예방 및 개선용 조성물 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100077583A KR101048657B1 (ko) | 2010-08-11 | 2010-08-11 | 실크 아미노산 및 티로신을 유효성분으로 포함하는 뇌질환 예방 및 개선용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101048657B1 true KR101048657B1 (ko) | 2011-07-12 |
Family
ID=44923501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100077583A KR101048657B1 (ko) | 2010-08-11 | 2010-08-11 | 실크 아미노산 및 티로신을 유효성분으로 포함하는 뇌질환 예방 및 개선용 조성물 |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR101048657B1 (zh) |
| CN (1) | CN103209697A (zh) |
| WO (1) | WO2012020991A2 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102107806B1 (ko) * | 2019-11-12 | 2020-05-07 | 주식회사 네이처센스 농업회사법인 | 기억력 및 인지기능 개선용 펩타이드 조성물 |
| KR102107804B1 (ko) * | 2019-11-12 | 2020-05-07 | 주식회사 네이처센스 농업회사법인 | 기억력 및 인지기능 개선용 펩타이드 |
| KR102107808B1 (ko) * | 2019-11-12 | 2020-05-07 | 주식회사 네이처센스 농업회사법인 | 기억력 및 인지기능 개선용 펩타이드 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6667194B2 (ja) * | 2014-04-28 | 2020-03-18 | 不二製油株式会社 | 脳神経疾患の予防又は脳機能改善用食品を製造するための食品添加物 |
| CN104606178A (zh) * | 2015-02-09 | 2015-05-13 | 李健 | 2-戊酰基-1,5-环己二烯-1-羧酸在制备治疗黄褐斑的药物中的应用 |
| JP2023532939A (ja) * | 2020-06-30 | 2023-08-01 | インダストリー－アカデミック コーオペレイション ファウンデーション キョンサン ナショナル ユニバーシティ | チロシンを有効成分として含むタンパク質内のチロシンのニトロ化による疾患の予防、改善または治療用組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030077902A (ko) * | 2002-03-27 | 2003-10-04 | 대한민국(부경대학교 총장) | 누에산물을 이용한 항치매환자식의 조성물 |
| KR100494358B1 (ko) * | 2004-07-30 | 2005-06-10 | 주식회사 바이오그랜드 | 두뇌 또는 인지 기능 증진용 조성물 |
| CN101163712B (zh) * | 2004-07-31 | 2012-04-25 | 脑保护株式会社 | 改善神经保护和神经功能作用的丝素肽及其制备方法 |
-
2010
- 2010-08-11 KR KR1020100077583A patent/KR101048657B1/ko active IP Right Grant
-
2011
- 2011-08-10 WO PCT/KR2011/005853 patent/WO2012020991A2/ko active Application Filing
- 2011-08-10 CN CN2011800493075A patent/CN103209697A/zh active Pending
Non-Patent Citations (2)
| Title |
|---|
| 논문1:Biotechnol J. * |
| 논문1:Biotechnol J.* |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102107806B1 (ko) * | 2019-11-12 | 2020-05-07 | 주식회사 네이처센스 농업회사법인 | 기억력 및 인지기능 개선용 펩타이드 조성물 |
| KR102107804B1 (ko) * | 2019-11-12 | 2020-05-07 | 주식회사 네이처센스 농업회사법인 | 기억력 및 인지기능 개선용 펩타이드 |
| KR102107808B1 (ko) * | 2019-11-12 | 2020-05-07 | 주식회사 네이처센스 농업회사법인 | 기억력 및 인지기능 개선용 펩타이드 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103209697A (zh) | 2013-07-17 |
| WO2012020991A3 (ko) | 2012-05-24 |
| WO2012020991A2 (ko) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101048657B1 (ko) | 실크 아미노산 및 티로신을 유효성분으로 포함하는 뇌질환 예방 및 개선용 조성물 | |
| US20120052138A1 (en) | Composition comprising green tea extract | |
| WO2021223346A1 (zh) | 山药蛋白提取物在制备治疗勃起功能障碍的药物中的应用 | |
| JP2022079551A (ja) | 筋線維化抑制用組成物 | |
| US20160008414A1 (en) | Pharmaceutical composition containing sceptridium japonicum extract for preventing or treating stroke or degenerative brain diseases | |
| JP2017137296A (ja) | アストロサイトのグルコース代謝活性化剤 | |
| WO2021080129A1 (ko) | 하이드란제놀 또는 필로둘신을 유효성분으로 하는 피부장벽 강화 및 아토피 피부염 개선용 조성물 | |
| KR101588247B1 (ko) | 뇌졸중 또는 퇴행성 뇌질환 예방 또는 치료용 조성물 | |
| WO2005044291A1 (en) | Grape seed extract having neuronal cell-protecting activity and the composition comprising the same for prepenting and treating degenerative brain disease | |
| US20180193401A1 (en) | Anti-obesity composition comprising natural complex | |
| JP2022110113A (ja) | エンテロコッカス・フェカーリス、その培養液またはその死菌体を有効成分として含有する筋肉の減退、低下及び筋萎縮の予防、改善または治療用の薬学組成物、食品組成物及び食品添加剤 | |
| JPWO2006030907A1 (ja) | 網膜保護剤 | |
| RU2493841C1 (ru) | Синергетический препарат для лечения сердечно-сосудистых заболеваний, сахарного диабета и заболеваний гепато-билиарной системы | |
| TW200938216A (en) | Use of black soybean for treating ophthalmic diseases | |
| KR101413771B1 (ko) | 잣잎 추출물을 함유하는 비만 억제용 조성물 | |
| KR101644755B1 (ko) | 뇌졸중 또는 퇴행성 뇌질환 예방 또는 치료용 조성물 | |
| KR20130133477A (ko) | 상황버섯 추출물의 전립선 비대증 개선, 여드름 개선, 발모 촉진 용도 | |
| WO2023080725A1 (ko) | 차풀 추출물을 유효성분으로 포함하는 에너지 대사 촉진 또는 개선용 조성물 | |
| KR102265793B1 (ko) | 금어초 추출물을 유효성분으로 함유하는 혈당 강하용 건강기능식품 조성물 | |
| CN109125334B (zh) | 毛蕊花糖苷在制备治疗新生儿缺氧缺血性脑病药物中的用途 | |
| EP2253228B1 (en) | Composition for controlling and improving female and male gametogenesis | |
| KR20120029585A (ko) | 혈당 강하용 두부 및 그 제조방법 | |
| KR20080094466A (ko) | 대사증후군 치료용 약제 조성물 | |
| WO2012138190A2 (ko) | 병아리꽃나무 추출물을 포함하는 조성물 | |
| CA3223282A1 (en) | Administration of baiba to increase benefit of losing weight of intermittent fasting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20140625 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20150622 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20160624 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20170705 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20190708 Year of fee payment: 9 |